SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

A quarterly earnings beat, rapid growth in AI-compute revenue and an aggressive expansion outlook are driving attention, alongside preliminary discussions of a possible Tesla merger. Many traders are bullish on the growth story and anticipate further gains, while skeptics question the valuation, heavy spending and credibility of Musks ambitious forecasts.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary update sharply raised its quarterly revenue and gross-margin outlook on stronger AI platform demand, driving a strong after-hours rally. Traders largely welcomed the results as evidence of improving business momentum and a possible short squeeze, while some questioned whether the gains would hold given the companys history of volatility and execution concerns.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings beat expectations, but a softer fourth-quarter outlook, slowing revenue growth, and a reduced advertising forecast have driven a sharp selloff. Traders are split between buying the dip on the companys profitability and buybacks, and warning that weaker growth and streaming competition could keep pressure on the shares.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces strong quarterly results and raised outlook are being overshadowed by a sharp selloff, extending traders frustration that earnings beats have not translated into gains. The debate centers on whether the decline is profit-taking and high expectations or reflects real concerns about cash flow, rising costs, supply constraints, and an insurance loss.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELHs move toward and briefly above the $30 level has traders focused on whether the stock can sustain a technical breakout, with some pointing to higher volume and others expecting another rejection. Pepsi buyout talk and hopes around earnings appear in the discussion, but remain speculation rather than a confirmed catalyst.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgicals Q3 earnings beat was followed by a sharp selloff, as traders focused on slower procedure growth, a cautious outlook and planned da Vinci pricing cuts, alongside a one-time antitrust settlement. Some investors view the reaction as excessive given continued business growth, while others see the growth and pricing pressures as reasons for caution.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares drew attention after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial, supporting a planned FDA resubmission. Traders are now debating the dilutive effect of the upsized public offering, priced below the recent trading level, against the added funding for development and potential commercialization.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is in focus ahead of its quarterly earnings report, with traders watching guidance and semiconductor-equipment demand amid a sharp pullback. The debate is split between buyers treating weakness and support levels as an opportunity and bears concerned about further sector pressure and high expectations.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention as traders anticipate the Phase 3 REGAL AML trial reaching its 80-event final-analysis trigger; the last disclosed count was 78, and traders are also watching for SLS009 updates. Some interpret the CEOs next chapter remarks and the companys ASH presence as possible buyout or partnership clues, while skeptics note there is no confirmed deal or trial result and view the rally as speculative.

Fabrinet engages in the provision of optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers (OEMs). The firm's services include process design and engineering, advanced optical packaging, printed circuit board assembly and test, new product introduction, supply chain and inventory management, and customized glass and crystal optics fabrication. The company was founded by David Thomas Mitchell on August 12, 1999 and is headquartered in George Town, Cayman Islands.

Fabrinet

Fabrinets sharp selloff despite an earnings beat and upbeat outlook is driving discussion, with traders pointing to weak free cash flow, heavy investment and working-capital needs as possible concerns. Others see the drop as an overreaction, citing continued AI data-center and optical-connectivity demand and debating whether the stock is oversold.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has changed its corporate name to Faeth Therapeutics, Inc. (the Company). The Companys common stock is expected to begin trading on the Nasdaq Capital Market under the new ticker symbol FTH on June 16, 2026, and the Company has...

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on June 1, 2026, the Compensation Committee of Senseis Board of Directors granted three new employees options to purchase an aggregate of 19,300 shares of the Companys common stock in connection with their employment...

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. The first quarter of 2026 was...

Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company, announced today that the first patient was dosed in Study FTH-PIK-101 (NCT07558733), a Phase 1b/2 trial of PIKTOR...

Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that Company management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16th, 2026 at 12:45 p.m...

Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the full year ended December 31, 2025, following its previously announced acquisition of Faeth Therapeutics and...

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on March 11, 2026, Senseis Board of Directors granted a new employee an option to purchase 166,435 shares of the Companys...

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on February 19, 2026, Senseis Board of Directors granted 17 new employees, in the aggregate, options to purchase 2,319,893...

Small Cap Stocks To Add to Your Watchlist - February 18th

Rackspace Technology, Direxion Daily PLTR Bear 1X Shares, Spring Valley Acquisition, Direxion Daily MU Bull 2X Shares, Sensei Biotherapeutics, Inflection Point Acquisition Corp. II, and Direxion...

 SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition

Equity

The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio.

Faeth Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Austin, TX.

Faeth Therapeutics Inc.

Bullish Sentiment

<ul class="summary-bullets"><li>The company also secured a private placement financing worth around $200 million.</li><li>Sensei Biotherapeutics plans to use the majority of the proceeds to advance PIKTOR.</li><li>Remaining funds will be used for the development of Sensei’s Phase 1/2 trial candidate, Solnerstotug.</li></ul>Shares of Sensei Biotherapeutics (SNSE) shot up over 200% on Wednesday after the company strengthened its oncology pipeline by announcing the acquisition of Faeth Therapeutics.<a href="https://stocktwits.com/symbol/SNSE">SNSE stock</a> rose to its highest since May 2024 and recorded its biggest-ever intraday gains. Trading in the stock was twice halted after the opening bell, according to Nasdaq data.The acquisition adds Faeth’s lead investigational therapy, PIKTOR, an all-oral drug combination that targets tumor metabolism and blocks multiple points in the PI3K/AKT/mTOR pathway, a critical cell signaling system that regulates cell survival, growth, and division.“In the PI3K pathway, the field has repeatedly run into the same constraint. Single-node inhibitors force a tradeoff between efficacy and tolerability. PIKTOR is designed to change that tradeoff by inhibiting PI3K-alpha and mTORC1/2 simultaneously, and we believe we can achieve more complete pathway suppression with improved tolerability,” said Anand Parikh, Co-founder of Faeth Therapeutics and the new COO and director of Sensei.<h2 class="st-heading-2">$200 Million Private Placement</h2>Sensei Biotherapeutics also secured private placement financing, worth about $200 million. The company plans to use most of the capital to advance PIKTOR, including topline results from an ongoing Phase 2 trial in second-line advanced endometrial cancer and the launch of a Phase 1b study in HR+/HER2- advanced breast cancer, both anticipated by the end of 2026.Remaining funds will support general corporate initiatives and the continued development of Sensei’s Phase 1/2 trial candidate, Solnerstotug.The private placement attracted participation from B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, and Vivo Capital, among other life sciences funds and institutional investors.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish,’ amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/SNSE_jpg_53f7157d12.webp" alt="SNSE.jpg">One user expects the stock to “go up big” if it holds above the $25.4 to $25.5 support. It is currently trading at around $28.<stembedurl>https://stocktwits.com/brewstocks123/message/645236001</stembedurl>Another user expects the stock to climb to $44 by the end of the session.<stembedurl>https://stocktwits.com/FreyBentos/message/645238839</stembedurl>The stock has gained around 160% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rxt-stock-soars-pre-market-palantir-connection/cZR0r6BR4vX">RXT Stock Soared 275% Today – What’s The Connection&nbsp;With Palantir?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Representative image of a trending stock chart.

Shares of Sensei Biotherapeutics (SNSE) shot up over 200% on Wednesday after the company strengthened its oncology pipeline by announcing the acquisition of Faeth Therapeutics.

First Trust Exchange-Traded Fund III - First Trust NYSE Arca Biotechnology Index Fund

iShares Biotechnology ETF

Sensei Biotherapeutics Inc

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$20.79
Prev Close	$19.44
Open	$19.04
Dividend Yield	0.00%
50-Day Moving Average	$30.82
Beta	1.01
Avg. Volume	446,809.07
PE Ratio	-0.15

52-Week High	$42.14
52-Week Low	$7.45
Market Capitalization	$502.34M
EPS (Annual)	-$16.72
Price to Book	3.11
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

SNSE Fundamentals